PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
January 1, 2016Circulation Journal66 citationsOpen Access

Diuretic Action of Sodium-Glucose Cotransporter 2 Inhibitors and Its Importance in the Management of Heart Failure

GKGenjiro Kimura

Key Result

SGLT2 inhibitors improve heart failure prognosis primarily through their loop diuretic-like action, though their combination with conventional diuretics requires caution due to potential dehydration and stroke risk.

Structured PICO

P
Population
Patients with heart failure and type 2 diabetes
I
Intervention
Sodium-glucose cotransporter 2 (SGLT2) inhibitors

SGLT2 inhibitors may act as loop diuretics, and their prognostic benefits in heart failure appear to be driven by this diuretic action, warranting caution when combined with conventional diuretics to avoid volume depletion and stroke.

Limitations

  • Combined use of SGLT2 inhibitors with conventional diuretics may induce massive diuresis, dehydration, and hypotension.
  • Potential increased risk of stroke when SGLT2 inhibitors are combined with other diuretics requires further investigation.

Abstract

Primarily, the sodium-glucose cotransporter 2 (SGLT2) inhibitors suppress the cotransport of glucose and sodium from the tubular lumen of the proximal tubules to the blood, and excrete glucose into the urine. Therefore, glucose and caloric balances become negative, reducing both the blood glucose level and insulin secretion. On the other hand, the proximal tubular fluid, constituted with low chloride concentration because of SGLT2 inhibition, is transferred to the loop of Henle. Under low chloride conditions, the reabsorption mechanisms in the loop of Henle do not work, similar to when loop diuretics are given. Subanalysis data on heart failure (HF) from the EMPA-REG OUTCOME trials are discussed, assuming that SGLT2 inhibitors are loop diuretics. Renin-angiotensin system inhibitors and β-blockers contribute to prognostic improvements of HF, independent of SGLT2 inhibitors, and therefore, both regimens are essential for the treatment of HF. On the other hand, the prognostic improvements by SGLT2 inhibitors are not significant under treatment including conventional diuretics such as loop diuretics and aldosterone antagonists, suggesting that the prognostic improvement in HF by SGLT2 inhibitors is mostly through their diuretic action. (Circ J 2016; 80: 2277-2281).

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Genjiro Kimura (2016) conducted a review in Heart failure and Type 2 diabetes. SGLT2 inhibitors vs. Conventional diuretics was evaluated. SGLT2 inhibitors improve heart failure prognosis primarily through their loop diuretic-like action, though their combination with conventional diuretics requires caution due to potential dehydration and stroke risk.

synapsesocial.com/papers/6aa10bbcc0e1046e90f7a8f6https://doi.org/10.1253/circj.cj-16-0780
Ask AI
Helpful
Bookmark
Share
View Full Paper